Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 69

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 69
---
 representing our 401(k) matching contributions, and $22,656 representing accrued vacation as of March 31, 2024 paid upon the adoption of unlimited paid time off policy. The amount for 2023 includes $987,500 for settlement of outstanding awards as of November 13, 2023 in connection with the Merger, $459 representing payments on Mr. Davis’ term life insurance policy, $900 representing reimbursement for cell phone expenses, and $9,900 representing our 401(k) matching contributions. For Dr. Kurtoglu, the amount for 2024 includes $630 representing payments on Dr. Kurtoglu’s term life insurance policy, $900 representing reimbursement for cell phone expenses, and $8,038 representing accrued vacation as of March 31, 2024 paid upon the adoption of unlimited paid time off policy. For Dr. Jewell, the amount for 2024 includes $420 representing payments on Dr. Jewell’s term life insurance policy, $900 representing reimbursement for cell phone expenses, $10,350 representing our 401(k) matching contributions, and $7,673 representing accrued vacation as of March 31, 2024 paid upon the adoption of unlimited paid time off policy.

<div align='center'>40</div>

(6) Dr. Kurtoglu was appointed Chief Operating Officer on November 13, 2023. On March 28, 2024, Dr. Kurtoglu’s title was changed to Chief Technology Officer.

(7) Dr. Jewell was appointed Chief Scientific Officer on November 13, 2023.

Narrative Disclosure to Summary Compensation Table

The primary elements of compensation for our Named Executive Officers are base salary, annual performance bonuses and equity-based compensation awards. The Named Executive Officers also participate in employee benefit plans and programs that we offer to our other full-time employees on the same basis.

#### Base Salaries
We pay our Named Executive Officers a base salary to compensate them for the satisfactory performance of services rendered to the Company. The base salary payable to each Named Executive Officer is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. Base salaries for our Named Executive Officers have generally been set at levels deemed necessary to attract and retain individuals with superior talent and were originally established in each Named Executive Officer’s employment agreement.

At the end of 2023, the Compensation Committee recommended to the Board, and the Board approved, an increase in Dr. Brunn’s annual base salary from $